In the last trading session, 7,355,425 shares of the Catabasis Pharmaceuticals, Inc.(NASDAQ:CATB) were traded, and its beta was 1.8. Most recently the company’s share price was $3.56, and it changed around $0.37 or 0.12% from the last close, which brings the market valuation of the company to $83.37 Million. CATB currently trades at a discount to its 52-week high of $8.59, offering almost -141.29% off that amount. The share price’s 52-week low was $1.25, which indicates that the current value has risen by an impressive 64.89% since then. We note from Catabasis Pharmaceuticals, Inc.’s average daily trading volume that its 10-day average is 2.51 Million shares, with the 3-month average coming to 10.22 Million.
Catabasis Pharmaceuticals, Inc. stock received a consensus recommendation rating of Hold, based on a mean score of 3. If we narrow it down even further, the data shows that none out of 1 analysts rate the stock as a Sell; another but none rate it as Overweight. Among the rest, 1 recommended CATB as a Hold, whereas none deemed it a Buy, and no one rated it as Underweight. Catabasis Pharmaceuticals, Inc. is expected to report earnings per share of -$0.45 for the current quarter.
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB): Trading Information
Instantly CATB has showed a green trend with a performance of 11.6% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of $3.85- on Friday, Feb 19 increased the stock’s daily price by 7.53%. The company’s shares are currently up 0.66% year-to-date, but still up 0.0171 over the last five days. On the other hand, Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) is 0.34% up in the 30-day period. We can see from the shorts that 1.13 Million shares have been sold at a short interest cover period of 0.11 day(s).
The consensus price target as assigned by Wall Street analysts is $24, which translates to bears needing to increase their stock price by 574.16% from its current value. Analyst projections state that CATB is forecast to be at a low of $24 and a high of $24. In order for the stock price to hit the forecast high, the stock would need to surge +574.16% from its current level, while the stock would need to crash 574.16% from its current level to reach the projected low.
Catabasis Pharmaceuticals, Inc. (CATB) projections and forecasts
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 31.7%. Catabasis Pharmaceuticals, Inc. earnings are expected to increase by 54.1% in 2021, but the outlook is negative 0% per year for the next five years.
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB)’s Biggest Investors
Upon looking at major shareholders, it appears that insiders hold 0.13% of Catabasis Pharmaceuticals, Inc. shares, and 40.64% of them are in the hands of institutional investors. The stock currently has a share float of 40.69%. Catabasis Pharmaceuticals, Inc. stock is held by 76 institutions, with Federated Hermes, Inc. being the largest institutional investor. By Sep 29, 2020, it held 15.18% of the shares, which is about 3.05 Million shares worth $18.87 Million.
Blackrock Inc., with 5.81% or 1.17 Million shares worth $2.5 Million as of Dec 30, 2020, holds the second largest percentage of outstanding shares.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.